PipelineReview.com1d
Aflibercept 8 mg met primary endpoint in phase III study and demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks ...
PipelineReview.com1d
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in ...
PipelineReview.com1d
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
NEW YORK, NY, USA I 17, 2024 I Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
PipelineReview.com1d
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with ...
PipelineReview.com1d
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
CHICAGO, IL and FORT WORTH, TX, USA I 17, 2024 I Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
PipelineReview.com1d
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
PARIS, France and Parsippany, NJ, USA I December 17, 2024 I Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today ...
PipelineReview.com1d
GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar
“The initiation of this Phase 3 trial and the dosing of the first patient are significant achievements in the development of SPD8,” said Dr. Mei-Chun Yang, CEO of GlycoNex. “As the demand for ...
PipelineReview.com1d
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
SINOVAC has initiated a phase I/II clinical trial on its bivalent vaccine in China since September 2023. The results from Phase I/II clinical trial demonstrated that the vaccine candidate has ...
PipelineReview.com1d
LIB Therapeutics Submits a Biologic License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol
CINCINNATI, OH, USA I 16, 2024 I LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company announced the submission of a ...
PipelineReview.com2d
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India
COPENHAGEN, Denmark I December 16, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN ® mpox vaccine with Serum Institute of India Pvt. Ltd.
PipelineReview.com2d
Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
LONDON, UK I December 16, 2024 I Accord Healthcare Limited (Accord) announces that the European Commission (EC) has granted marketing authorisation for ...